Since fatty acid synthase (FASN) is a rate-limiting enzyme in de novo lipogenesis, reducing fatty acid synthesis by inhibiting FASN is a promising strategy to mitigate lipid peroxidation in AD. This evidence concerns the gene FASN and Alzheimer disease.